Patient and Oncology Nurse Preferences for the Treatment Options in Advanced Melanoma: A Discrete Choice Experiment

Frank Xiaoqing Liu, Edward A. Witt, Scot Ebbinghaus, Grace Dibonaventura Beyer, Enrique Basurto, Richard W Joseph

Research output: Contribution to journalArticle

Abstract

Background Understanding the perceptions of patients and oncology nurses about the relative importance of benefits and risks associated with newer treatments of advanced melanoma can help to inform clinical decision-making. Objectives The aims of this study were to quantify and compare the views of patients and oncology nurses regarding the importance of attributes of treatments of advanced melanoma. Methods A discrete choice experiment (DCE) was conducted in US-based oncology nurses and patients diagnosed with advanced melanoma. Patients and nurses were enlisted through online panels. In a series of scenarios, respondents had to choose between 2 hypothetical treatments, each with 7 attributes: mode of administration (MoA), dosing schedule (DS), median duration of therapy (DoT), objective response rate (ORR), progression-free survival (PFS), overall survival (OS), and grade 3 or 4 adverse events (AEs). Hierarchical Bayesian logistic regression models were used to estimate preference weights. Results A total of 200 patients with advanced melanoma and 150 oncology nurses participated. The relative importance estimates of attributes by patients and nurses, respectively, were as follows: OS, 33% and 28%; AEs, 29% and 26%; ORR, 25% and 27%; PFS, 12% and 15%; DS, 2% and 3%; DoT, 0% and 0%; and MoA, 0% and 0%. Conclusion Both patients and oncology nurses valued OS, ORR, and AEs as the most important treatment attributes for advanced melanoma, followed by PFS, whereas DS, DoT, and MoA were given less value in their treatment decisions. Implications for Practice Oncology nurses and patients have similar views on important treatment considerations for advanced melanoma, which can help build trust in shared decision-making.

Original languageEnglish (US)
Pages (from-to)E52-E59
JournalCancer Nursing
Volume42
Issue number1
DOIs
StatePublished - Jan 1 2019

Fingerprint

Melanoma
Nurses
Disease-Free Survival
Appointments and Schedules
Therapeutics
Survival
Logistic Models
Decision Making
Weights and Measures

Keywords

  • Advanced melanoma
  • Discrete choice experiments
  • Immunotherapy
  • Nurse preferences
  • Patient preferences

ASJC Scopus subject areas

  • Oncology
  • Oncology(nursing)

Cite this

Patient and Oncology Nurse Preferences for the Treatment Options in Advanced Melanoma : A Discrete Choice Experiment. / Liu, Frank Xiaoqing; Witt, Edward A.; Ebbinghaus, Scot; Dibonaventura Beyer, Grace; Basurto, Enrique; Joseph, Richard W.

In: Cancer Nursing, Vol. 42, No. 1, 01.01.2019, p. E52-E59.

Research output: Contribution to journalArticle

Liu, Frank Xiaoqing ; Witt, Edward A. ; Ebbinghaus, Scot ; Dibonaventura Beyer, Grace ; Basurto, Enrique ; Joseph, Richard W. / Patient and Oncology Nurse Preferences for the Treatment Options in Advanced Melanoma : A Discrete Choice Experiment. In: Cancer Nursing. 2019 ; Vol. 42, No. 1. pp. E52-E59.
@article{61fd20b7857d40c2a61706fa72efac07,
title = "Patient and Oncology Nurse Preferences for the Treatment Options in Advanced Melanoma: A Discrete Choice Experiment",
abstract = "Background Understanding the perceptions of patients and oncology nurses about the relative importance of benefits and risks associated with newer treatments of advanced melanoma can help to inform clinical decision-making. Objectives The aims of this study were to quantify and compare the views of patients and oncology nurses regarding the importance of attributes of treatments of advanced melanoma. Methods A discrete choice experiment (DCE) was conducted in US-based oncology nurses and patients diagnosed with advanced melanoma. Patients and nurses were enlisted through online panels. In a series of scenarios, respondents had to choose between 2 hypothetical treatments, each with 7 attributes: mode of administration (MoA), dosing schedule (DS), median duration of therapy (DoT), objective response rate (ORR), progression-free survival (PFS), overall survival (OS), and grade 3 or 4 adverse events (AEs). Hierarchical Bayesian logistic regression models were used to estimate preference weights. Results A total of 200 patients with advanced melanoma and 150 oncology nurses participated. The relative importance estimates of attributes by patients and nurses, respectively, were as follows: OS, 33{\%} and 28{\%}; AEs, 29{\%} and 26{\%}; ORR, 25{\%} and 27{\%}; PFS, 12{\%} and 15{\%}; DS, 2{\%} and 3{\%}; DoT, 0{\%} and 0{\%}; and MoA, 0{\%} and 0{\%}. Conclusion Both patients and oncology nurses valued OS, ORR, and AEs as the most important treatment attributes for advanced melanoma, followed by PFS, whereas DS, DoT, and MoA were given less value in their treatment decisions. Implications for Practice Oncology nurses and patients have similar views on important treatment considerations for advanced melanoma, which can help build trust in shared decision-making.",
keywords = "Advanced melanoma, Discrete choice experiments, Immunotherapy, Nurse preferences, Patient preferences",
author = "Liu, {Frank Xiaoqing} and Witt, {Edward A.} and Scot Ebbinghaus and {Dibonaventura Beyer}, Grace and Enrique Basurto and Joseph, {Richard W}",
year = "2019",
month = "1",
day = "1",
doi = "10.1097/NCC.0000000000000557",
language = "English (US)",
volume = "42",
pages = "E52--E59",
journal = "Cancer Nursing",
issn = "0162-220X",
publisher = "Lippincott Williams and Wilkins",
number = "1",

}

TY - JOUR

T1 - Patient and Oncology Nurse Preferences for the Treatment Options in Advanced Melanoma

T2 - A Discrete Choice Experiment

AU - Liu, Frank Xiaoqing

AU - Witt, Edward A.

AU - Ebbinghaus, Scot

AU - Dibonaventura Beyer, Grace

AU - Basurto, Enrique

AU - Joseph, Richard W

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Background Understanding the perceptions of patients and oncology nurses about the relative importance of benefits and risks associated with newer treatments of advanced melanoma can help to inform clinical decision-making. Objectives The aims of this study were to quantify and compare the views of patients and oncology nurses regarding the importance of attributes of treatments of advanced melanoma. Methods A discrete choice experiment (DCE) was conducted in US-based oncology nurses and patients diagnosed with advanced melanoma. Patients and nurses were enlisted through online panels. In a series of scenarios, respondents had to choose between 2 hypothetical treatments, each with 7 attributes: mode of administration (MoA), dosing schedule (DS), median duration of therapy (DoT), objective response rate (ORR), progression-free survival (PFS), overall survival (OS), and grade 3 or 4 adverse events (AEs). Hierarchical Bayesian logistic regression models were used to estimate preference weights. Results A total of 200 patients with advanced melanoma and 150 oncology nurses participated. The relative importance estimates of attributes by patients and nurses, respectively, were as follows: OS, 33% and 28%; AEs, 29% and 26%; ORR, 25% and 27%; PFS, 12% and 15%; DS, 2% and 3%; DoT, 0% and 0%; and MoA, 0% and 0%. Conclusion Both patients and oncology nurses valued OS, ORR, and AEs as the most important treatment attributes for advanced melanoma, followed by PFS, whereas DS, DoT, and MoA were given less value in their treatment decisions. Implications for Practice Oncology nurses and patients have similar views on important treatment considerations for advanced melanoma, which can help build trust in shared decision-making.

AB - Background Understanding the perceptions of patients and oncology nurses about the relative importance of benefits and risks associated with newer treatments of advanced melanoma can help to inform clinical decision-making. Objectives The aims of this study were to quantify and compare the views of patients and oncology nurses regarding the importance of attributes of treatments of advanced melanoma. Methods A discrete choice experiment (DCE) was conducted in US-based oncology nurses and patients diagnosed with advanced melanoma. Patients and nurses were enlisted through online panels. In a series of scenarios, respondents had to choose between 2 hypothetical treatments, each with 7 attributes: mode of administration (MoA), dosing schedule (DS), median duration of therapy (DoT), objective response rate (ORR), progression-free survival (PFS), overall survival (OS), and grade 3 or 4 adverse events (AEs). Hierarchical Bayesian logistic regression models were used to estimate preference weights. Results A total of 200 patients with advanced melanoma and 150 oncology nurses participated. The relative importance estimates of attributes by patients and nurses, respectively, were as follows: OS, 33% and 28%; AEs, 29% and 26%; ORR, 25% and 27%; PFS, 12% and 15%; DS, 2% and 3%; DoT, 0% and 0%; and MoA, 0% and 0%. Conclusion Both patients and oncology nurses valued OS, ORR, and AEs as the most important treatment attributes for advanced melanoma, followed by PFS, whereas DS, DoT, and MoA were given less value in their treatment decisions. Implications for Practice Oncology nurses and patients have similar views on important treatment considerations for advanced melanoma, which can help build trust in shared decision-making.

KW - Advanced melanoma

KW - Discrete choice experiments

KW - Immunotherapy

KW - Nurse preferences

KW - Patient preferences

UR - http://www.scopus.com/inward/record.url?scp=85058707714&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85058707714&partnerID=8YFLogxK

U2 - 10.1097/NCC.0000000000000557

DO - 10.1097/NCC.0000000000000557

M3 - Article

VL - 42

SP - E52-E59

JO - Cancer Nursing

JF - Cancer Nursing

SN - 0162-220X

IS - 1

ER -